Abstract
Background
Methods
Results
Conclusion
Notes
Ethics statement
The study protocol was reviewed and approved by the Institutional Review Board of Dong-A University on July 26, 2023 (No. 23-135). Written informed consent was obtained from all the participants.
REFERENCES
Table 1.
Variable | Overall (n=12) | Synchronous (n=6) | Metachronous (n=6) | P-value |
---|---|---|---|---|
Age (yr) | 69.6±14 | 62.3±13 | 76.8±12 | 0.09a) |
Male | 8 (67) | 5 (83) | 3 (50) | 0.55b) |
Hypertension | 9 (75) | 3 (50) | 6 (100) | 0.18b) |
Diabetes mellitus | 5 (42) | 2 (33) | 3 (50) | 1.00b) |
Dyslipidemia | 6 (50) | 2 (33) | 4 (67) | 0.57b) |
Smoking | 5 (42) | 3 (50) | 2 (33) | 1.00b) |
Pre-existing atrial fibrillation | 0 | 0 | 0 | - |
History of coronary artery disease | 3 (25) | 0 | 3 (50) | 0.18b) |
Prior use of antithrombotics | 0.18b) | |||
None | 9 (75) | 6 (100) | 3 (50) | |
Single antiplatelet | 2 (17) | 0 | 2 (33) | |
Dual antiplatelet | 1 (8) | 0 | 1 (17) | |
Acute ischemic stroke onset-to-door time | 1.00b) | |||
≤6 hr | 5 (42) | 3 (50) | 2 (33) | |
>6 hr | 7 (58) | 3 (50) | 4 (67) | |
NIHSS on admission | 5 (0–18) | 3.5 (0–18) | 12.5 (2–17) | 0.26a) |
TOAST classification | 0.26b) | |||
Large artery atherosclerosis | 4 (33) | 2(33) | 2 (33) | |
Small vessel occlusion | 1 (8) | 0 | 1 (17) | |
Cardioembolism | 5 (42) | 4(66) | 1 (17) | |
Other determined | 1 (8) | 0 | 1 (17) | |
Undetermined | 1 (8) | 0 | 1 (17) | |
Type of MI | 0.24b) | |||
ST elevation MI | 7 (58) | 5 (83) | 2 (33) | |
Non-ST elevation MI | 5 (42) | 1 (17) | 4 (67) | |
Ejection fraction in echocardiogram | 1.00b) | |||
Reduced (<40%) | 5 (42) | 3 (50) | 2 (33) | |
Mid-range (40%–50%) | 3 (25) | 1 (17) | 2 (33) | |
Preserved (≥50%) | 4 (33) | 2 (33) | 2 (33) | |
New-onset atrial fibrillation | 2 (17) | 2 (33) | 0 | 0.46b) |
Presence of thrombus | 1 (8) | 1 (17) | 0 | 1.00b) |
Table 2.
CCI, cardiocerebral infarction; NIHSS, National Institutes of Health Stroke Scale; TOAST, the Trial of Org 10172 in Acute Stroke Treatment; V/S, vital sign; BP, blood pressure; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; EF, ejection fraction; DM, diabetes mellitus; DL, dyslipidemia; Lt, left; PICA, posterior inferior cerebellar artery; NSTEMI, non–ST-elevation myocardial infarction; dRCA, distal segment of right coronary artery; RCA-PL, right coronary artery posterolateral segment; DCMP, dilated cardiomyopathy; HTN, hypertension; TIA, transient ischemic attack; STEMI, ST-elevation myocardial infarction; dLAD, distal segment of left anterior descending artery; AF, atrial fibrillation; Smk, smoking; Rt, right; MCA, middle cerebral artery; mRCA, middle segment of right coronary artery; dLCX, distal segment of left circumflex artery; pLAD, proximal segment of left anterior descending artery; mLAD, middle segment of left anterior descending artery; ACA, anterior cerebral artery; LV thrombus, left ventricular thrombus; pRCA, proximal segment of right coronary artery; d/t, due to; VD, vessel disease; LAD OS, left anterior descending artery ostium; CABG, coronary artery bypass grafting; SVG, saphenous vein graft; OM, obtuse marginal branch; LCX OS, left circumflex artery ostium; AHF, acute heart failure.